Advancing Cancer Care for Dogs
Peer Reviewed by Nature™: Remarkable Survival Gains for Canine Cancer Patients. See how we work with:
We are transforming canine cancer care through ongoing scientific research and innovation in therapeutic treatments.
New approaches to the development of cancer therapeutics are urgently needed to improve the current 89% failure rate of novel drugs in clinical trials, and to improve patient outcomes. Spontaneous cancer in companion animals represents a unique opportunity for investigation of novel therapeutics for human and veterinary use
Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials
Dog cancer research advances pursuit of drugs for humans and canines
Published June 19, 2023 | Compelling genetic data, increased funding and growing collaborations in the past decade are pushing forward development of cancer drugs for both canines and humans
Could Fido lead us to better cancer drugs?
Despite a growing number of targeted cancer treatments in development each year, few are able to reach cancer patients due to the rate at which evidence is generated from human clinical trials
World’s largest genomic study of canine cancer reveals potential for novel human cancer treatments
Researchers from Stanford AI Health and One Health, the world’s first translational canine cancer care company, published the results from the largest-ever genomic study of canine cancer which revealed a promising path for enhanced human cancer treatments.
There’s no “one-size-fits-all” treatment for cancer. That’s why FidoCure® uses genomic testing to determine the best course of action for your dog’s cancer therapy – beyond standard chemo and radiation.
FidoCure® Approach: Genetic testing reveals which targeted therapies may work best for your dog
Precision medicine can offer a hopeful prognosis. FidoCure® was created by dog lovers and scientists on a mission to make effective canine cancer treatment accessible. Our process uses genomic testing in conjunction with tumor type to identify possible cancer-causing mutations. From there, we suggest targeted therapy to precisely attack the cancer cells.
Forrest was diagnosed with splenic cancer and given one month to live.
Through the targeted therapy suggested by FidoCure®, he lived happily for nearly 4 years past his diagnosis.
Forrest, Golden Retriever
Hemophagocytic Histiocytic Sarcoma
Thousands of dogs have benefited from FidoCure® when other options were limited.
Toulouse
“Since starting treatment, Toulouse’s tumors have regressed. FidoCure® brought us hope for Toulouse when we thought we didn’t have any options left.” — Daniel, FL
Lizzie
“Thanks to FidoCure®, Lizzie is 100% active again, eating well, and in remission for 5 months.” — Kimberley and Francois, CT
Gracie
“[Our vet] told us about the One Health Company’s precision medicine solution, FidoCure®… Now, exactly two months later, Gracie’s cancer is in remission.” — The Gonzalez Family, FL
